Drugs in Dev. Neurology
IND Enabling
United Kingdom 
Lead Product(s) : PTD802
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pheno Gets Clinical Trial Authorization for PTD802 in Multiple Sclerosis
Details : PTD802 is a novel small molecule therapeutic designed to promote remyelination by inhibiting GPR17. It is being investigated for multiple sclerosis.
Product Name : PTD802
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : PTD802
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SPR301
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Spur Therapeutics Develops Gene Therapy Candidate for Parkinson’s Disease
Details : SPR301 is an AAV9 capsid which can counteract the reduced GCase activity caused by these mutations, potentially providing a gene therapy that changes the lives of people with GBA1 Parkinson’s disease.
Product Name : SPR301
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : SPR301
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Foralumab
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tiziana Doses First Patient with Moderate Alzheimer’s Disease with Foralumab
Details : Tiziana’s intranasal TZLS-401 (foralumab), is the only fully human anti-CD3 mAb that is being evaluated in patients with moderate Alzheimer’s disease.
Product Name : TZLS-401
Product Type : Antibody
Upfront Cash : Inapplicable
June 26, 2024
Lead Product(s) : Foralumab
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urcosimod
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response to treat Neuropathic Corneal Pain.
Product Name : OK-101
Product Type : Peptide
Upfront Cash : Inapplicable
September 10, 2023
Lead Product(s) : Urcosimod
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Foralumab
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tiziana’s intranasal TZLS-401 (foralumab), is the only fully human anti-CD3 mAb and has demonstrated a favorable safety profile and clinical response in patients with alzheimer’s disease.
Product Name : TZLS-401
Product Type : Antibody
Upfront Cash : Inapplicable
August 15, 2023
Lead Product(s) : Foralumab
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urcosimod
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Tufts Medical Center
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to evaluate the efficacy and safety of OK-101, a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, in patients with neuropathic corneal pain.
Product Name : OK-101
Product Type : Peptide
Upfront Cash : Undisclosed
July 28, 2023
Lead Product(s) : Urcosimod
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Tufts Medical Center
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : MTX325
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MTX325 is a USP30 inhibitor small molecule drug candidate, which is currently being evaluated in clinical trial studies with patients for the treatment of parkinson's disease.
Product Name : MTX325
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 12, 2023
Lead Product(s) : MTX325
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BEN-34712
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : The Sheffield Institute for Translational Neuroscience
Deal Size : Inapplicable
Deal Type : Inapplicable
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS into IND-Enabling Studies
Details : BEN-34712 is an oral, potent and selective brain penetrant RARɑβ (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies for amyotrophic lateral sclerosis.
Product Name : BEN-34712
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2023
Lead Product(s) : BEN-34712
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : The Sheffield Institute for Translational Neuroscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MRx0005
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IND clearance marks the expansion of the comany's pipeline single strain Live Biotherapeutics of MRx0005 and MRx0029 in development for the treatment of neurodegenerative conditions such as Parkinson’s disease via the gut-brain axis.
Product Name : MRx0005
Product Type : Microorganism
Upfront Cash : Inapplicable
February 22, 2022
Lead Product(s) : MRx0005
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SNP318
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : SciNeuro Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, SciNeuro will receive a worldwide license to intellectual property covering certain GSK Lp-PLA2 inhibitors including SNP318 and will be responsible for their further development through clinical proof-of-concept (PoC).
Product Name : SNP318
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 06, 2022
Lead Product(s) : SNP318
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : SciNeuro Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
